Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®

Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®

Sep 27, 2015
Source URL: https://qa1.novartis.us/news/media-releases/patients-aggressive-form-melanoma-lived-more-two-years-average-when-taking-novartis-therapies-tafinlar-mekinist-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/patients-aggressive-form-melanoma-lived-more-two-years-average-when-taking-novartis-therapies-tafinlar-mekinist-0